Treatment options for localized prostate cancer.
Am Fam Physician., Aug;84(4):413-20 (2011)
Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.
J. Urol., May;183(5):1822-8 (2010)
Words of wisdom. Re: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Eur. Urol., Feb;55(2):522-3 (2009)
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.
J. Proteome Res., Feb;8(2):620-30 (2009)
Overexpression of alpha-defensin is associated with bladder cancer invasiveness.
Urol. Oncol., 24(2):97-108 (2006)
Laparoscopic radical prostatectomy: evaluation of specimen pathologic features to critically assess and modify surgical technique.
Urology., Sep;66(3):552-6 (2005)
Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer.
J. Endourol., Apr;19(3):318-26 (2005)
Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
World J Urol., Feb;23(1):47-9 (2005)
Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Cancer Immunol. Immunother., Sep;52(9):535-45 (2003)
Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
J. Immunother., 27(1):13-26 (2004)
Application of a novel protein chip mass spectrometry technology for the identification of bladder cancer-associated biomarkers.
Adv. Exp. Med. Biol., 539(Pt A):47-60 (2003)
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures.
Prostate Cancer Prostatic Dis., Dec;2(5/6):264-276 (1999)
Sural nerve graft during laparoscopic radical prostatectomy. Initial experience.
Urol. Oncol., 7(5):191-4 (2002)
Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present.
Urology., Sep;56(3):436-9 (2000)
Luteinizing hormone-releasing hormone monotherapy: a viable option for treatment of prostate cancer?
Urology., Aug;58(2 Suppl 1):10-5 (2001)
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
Cancer Res., Jul;62(13):3609-14 (2002)
Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.
Clin. Cancer Res., Aug;8(8):2541-52 (2002)
An evaluation of bicalutamide in the treatment of prostate cancer.
Expert Opin Pharmacother., Sep;3(9):1313-28 (2002)
Intravesical dimethyl sulfoxide for primary amyloidosis of the bladder.
Urology., Dec;52(6):1136-8 (1998)
Conservative surgical therapy for penile and urethral carcinoma.
Urology., Feb;53(2):386-92 (1999)